Skip to main content
SHANGHAI INNOSTAR BIO-TECH CO., LTD. logo

SHANGHAI INNOSTAR BIO-TECH CO., LTD. — Investor Relations & Filings

Ticker · 688710 ISIN · CNE1000078J7 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 187 across all filing types
Latest filing 2026-05-21 Major Shareholding Noti…
Country CN China
Listing Shanghai Stock Exchange 688710

About SHANGHAI INNOSTAR BIO-TECH CO., LTD.

https://www.innostarbio.com/

Shanghai Innostar Bio-Tech Co., Ltd. is a contract research organization (CRO) focused on preclinical drug safety assessment and evaluation. The company provides integrated services including toxicology, safety pharmacology, pharmacokinetics, pharmacodynamics, and bioanalysis. It operates facilities compliant with international Good Laboratory Practice (GLP) standards, supporting regulatory submissions to agencies such as the NMPA and FDA. Innostar specializes in the non-clinical evaluation of small molecule drugs, biologics, and advanced therapies like cell and gene products. Its technical platforms support drug metabolism studies and biomarker discovery, aiming to streamline the transition from laboratory research to clinical development. The organization emphasizes a rigorous quality management system to ensure data integrity and reliability for global pharmaceutical and biotechnology clients.

Recent filings

Filing Released Lang Actions
简式权益变动报告书
Major Shareholding Notification Classification · 92% confidence The document is a “简式权益变动报告书” (Simplified Equity Change Report) filed by a major shareholder (information disclosure obligor) describing its reduction of stake below a 5% threshold in the listed company. This is not a company buyback (POS) nor an insider director trade (DIRS), but rather a notification of a significant shareholding change crossing the regulatory threshold. Thus it best fits the Major Shareholding Notification category (MRQ).
2026-05-21 Chinese
关于公司全资子公司获得NMPA GLP认证的公告
Regulatory Filings Classification · 78% confidence The document is a public announcement by Shanghai Yinuosi Biotechnology Co., Ltd. concerning its subsidiary obtaining GLP certification from the NMPA. It is not a financial report, earnings release, management change, share transaction, merger activity, or proxy material. Rather, it is a general regulatory announcement. Therefore, it falls under the "Regulatory Filings" category (RNS).
2026-05-21 Chinese
股东询价转让结果报告书暨持股5%以上股东持有权益比例降至5%以下的提示性公告
Major Shareholding Notification Classification · 92% confidence The document is an announcement by Shanghai Yinuosi Biotech Co., Ltd. regarding the price inquiry share transfer by a >5% shareholder and its shareholding reduction from 6.82% to 4.31%. It provides detailed information on the transfer, thresholds crossed (below 5%), change in shareholding proportions, and is a regulatory disclosure of a material shareholding change by a significant shareholder. This fits the Major Shareholding Notification category.
2026-05-21 Chinese
国泰海通证券股份有限公司关于上海益诺思生物技术股份有限公司股东向特定机构投资者询价转让股份的核查报告
Regulatory Filings Classification · 91% confidence The document is a detailed underwriter’s due-diligence "核查报告" on a shareholder’s off-market share transfer to qualified institutional investors, prepared to satisfy regulatory and listing rule requirements rather than announcing a financing deal or a management change. It is not an annual or quarterly report, earnings release, merger document, or issuance notice, but a compliance filing, making "Regulatory Filings (RNS)" the correct category.
2026-05-21 Chinese
2025年年度股东会会议资料
AGM Information Classification · 94% confidence The document is titled “2025年年度股东会会议资料” and contains detailed materials for the 2025 Annual General Meeting (AGM), including meeting notices, agenda, proposals for vote, board reports, profit distribution plans, and other items for shareholder consideration. It does not present full financial statements or quarterly results but serves as AGM presentation materials. Therefore, it falls under AGM Information.
2026-05-19 Chinese
股东询价转让定价情况提示性公告
Regulatory Filings Classification · 30% confidence The document is an official announcement (“公告”) by Shanghai Yinuosi Biotech regarding the preliminary pricing of a shareholder block transfer by an existing shareholder (Zhangjiang Biopharma Base) to institutional investors. It does not involve new share issuance, capital structure change by the company, dividend notice, director dealing, or an actual financial report. It is a standalone disclosure filing that does not fit any specific category such as MRQ (no threshold-crossing notification) or SHA (no new issue). Therefore it falls under the general regulatory announcement/fallback category: RNS.
2026-05-18 Chinese

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.